Argenx Bvba

Argen-x N.v.

Nicolas Ongenae

Torsten Dreier

Christophe Blanchetot

Sebastian Paul Van Der Woning

Johannes De Haard

Natalie De Jonge

The present invention provides binding molecules (e.g., antibodies or antigen binding fragments thereof) that specifically bind to and inhibit the biological activity of IL-6 (e.g., human, mouse and non-human primate IL-6). In a preferred embodiment, the antibodies or antigen binding fragments of the invention bind to IL-6 and inhibit its binding to an IL-6 receptor. Such antibodies or antigen binding fragments are particularly useful for treating IL-6-associated diseases or disorders (e.g., inflammatory disease and cancer).

Growing community of inventors

Gentbrugge, Belgium

Nicolas Ongenae